Parkinson’s disease is a neurodegenerative disorder that exemplifies the rising need for effective treatments for these disabling and progressive conditions. Over one million people are now affected in the U.S. Motor disabilities such as tremor, rigidity and slowing of voluntary movement characterize this disorder, although cognitive, behavioral and other symptoms often occur. Current treatments, while effective initially, ultimately produce disabling adverse effects. All fail to delay onset or prevent progression. While the cause remains obscure, recent research has begun to identify contributory factors whose inhibition could prove clinically beneficial. The Chase Therapeutics team has extensive experience in this field and stands poised to make significant advances in the pharmacotherapy of Parkinson’s disease and related neurodegenerative disorders.
Major Depressive Disorder
Major depressive disorder afflicts over 200 million people worldwide. Characterized by a persistently depressed mood, major depressive disorder is often associated with feelings of low self-esteem and a loss of interest in normal activities. Some patients have continuing symptoms, while others experience periods of depression separated by normal intervals. Major depressive disorder can negatively affect a person’s work and social life, as well eating, sleeping and general health. Although commonly attributed to a combination of genetic, environmental and psychological factors, the precise cause is unknown. Current treatments are slow to act (possibly weeks to months) and commonly produce intolerable adverse effects or fail to benefit those in need.